Dwight Silvera, MD
Ophthalmology · Evansville, INNPI 1376553487
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. ANI Pharmaceuticals, Inc. accounts for 60.7% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $13,330, 4.1 times the $3,213 reported in 2019. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 271 payments — averaging $103.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ANI Pharmaceuticals, Inc.$17K
- Johnson & Johnson Surgical Vision, Inc.$5K
- Alcon$902
- Bausch & Lomb, A Division Of Bausch Health US, LLC$646
- Carl Zeiss Meditec USA, Inc.$617
- Bausch & Lomb Americas Inc.$573
- plus $3K from 24 others
What the payments were for
- Consulting fees$3,73213%
- Speaking & faculty fees$15,82556%
- Travel & lodging$1,1454%
- Food & beverage$6,65324%
- Education$1961%
- Other$5142%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 35 | $17,040 |
| Johnson & Johnson Surgical Vision, Inc. | 27 | $5,484 |
| Alcon | 25 | $902 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 37 | $646 |
| Carl Zeiss Meditec USA, Inc. | 5 | $617 |
| Bausch & Lomb Americas Inc. | 26 | $573 |
| Glaukos Corporation | 14 | $399 |
| Mallinckrodt Hospital Products Inc. | 13 | $395 |
| Novartis | 17 | $382 |
| Shire North American Group Inc | 8 | $347 |
| Regeneron Healthcare Solutions, Inc. | 12 | $250 |
| Sun Pharmaceutical Industries Inc. | 13 | $212 |
| AbbVie | 2 | $115 |
| Amgen(2 entities) | 4 | $87 |
| Mallinckrodt Enterprises LLC | 3 | $82 |
| Rxsight Inc | 1 | $69 |
| Oyster Point Pharma, Inc. | 3 | $68 |
| NEW World Medical,inc. | 5 | $58 |
| Eyepoint US, Inc. | 3 | $45 |
| Dompe US, Inc. | 2 | $42 |
| Apellis Pharmaceuticals, Inc. | 2 | $41 |
| Aerie Pharmaceuticals, Inc. | 2 | $33 |
| Biotissue Holdings Inc. | 3 | $32 |
| Kala Pharmaceuticals, Inc. | 2 | $28 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Sight Sciences, Inc. | 2 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| Sandoz | 1 | $21 |
| Harrow Eye, LLC | 1 | $15 |
| Quidel Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PURIFIED CORTROPHIN GEL$16,561
- Premium Cataract IOLs$836
- Tecnis Symfony IOL$732
- LUMERA 700$514
- Luxor$139
- AcrySof IQ PanOptix$137
- XIIDRA$123
How this compares
$28,064 in reported general payments places this provider in the 95th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CortrophinCorticotropin | 30 | $1,968,720 |
| Lotemax SmLoteprednol Etabonate | 379 | $96,053 |
| Prednisolone Acetate | 1,701 | $49,938 |
| ProlensaBromfenac Sodium | 83 | $28,921 |
| XiidraLifitegrast | 28 | $19,200 |
| Bromfenac Sodium | 86 | $16,569 |
| Ketorolac Tromethamine | 1,137 | $15,789 |
| MieboPerfluorohexyloctane/Pf | 17 | $12,689 |
| RestasisCyclosporine | 16 | $10,457 |
| Trifluridine | 66 | $10,072 |
| CombiganBrimonidine Tartrate/Timolol | 27 | $7,900 |
| Tobramycin | 1,432 | $7,886 |
| Tobradex StTobramycin/Dexamethasone | 31 | $7,799 |
| Loteprednol Etabonate | 30 | $5,892 |
| ValacyclovirValacyclovir Hcl | 59 | $3,572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Loteprednol Etabonate | $646 | $130,865492 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $573 | $31,88945 claims |
| AbbVieRestasis, Combigan | $115 | $18,35843 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Evansville
- Omar DukarEvansville$43K
- David MalitzEvansville$12K
- Andrew StrandEvansville$12K
- Drew SommervilleEvansville$8K
- Matthew BoyerEvansville$6K
- Karishma HabbuEvansville$4K
- Jonathan WeyerEvansville$4K
- Sally PrimusEvansville$4K
- Shamik BafnaLafayette$505K
- Kevin WaltzIndianapolis$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.